MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc. (CXM) Addresses The High Cost Of Heart Surgery 0 comments
    Apr 1, 2013 9:39 PM | about stocks: CXM

    The number and degree of medical advances over the past 50 years is astonishing, offering hope for the afflicted never before possible or even imaginable. But it's hope that comes with a very steep price. Regardless of who pays the bill, or how efficiently everything is administered, the cost of applying the latest technologies is going to be high, whether in the form of drugs, diagnostic instrumentation, or complex surgeries. As existing technologies mature, costs can decrease, but the use of mature technologies is inevitably replaced by a demand for even newer drugs, instrumentation, and procedures. When a loved one's life is at stake, everyone wants the best.

    In the case of heart disease, the world's #1 killer, the costs can be staggering. Angioplasty and stent procedures to improve blood flow to the heart can cost tens of thousands of dollars, and coronary bypass surgery can cost hundreds of thousands of dollars. Multiply such costs by the number of patients who receive coronary revascularizations each year (over a million in the U.S. alone), together with the costs associated with all of the complications that can result, and the impact on healthcare costs becomes clear.

    Such numbers drive home the importance of Generx, the lead clinical development product candidate of Cardium Therapeutics. Unlike traditional heart treatment drugs that only treat the pain of heart blood flow problems, requiring expensive procedures like the above to deal with actual blood flow, Generx is able to stimulate the growth of blood vessels in the heart. As a cost-effective and easy-to-apply alternative to invasive procedures, the target market for the drug is deep and worldwide. In countries where the access to technology and associated funding is limited, Generx could represent a desperately needed option. The drug has already completed four randomized clinical studies in the U.S. and Europe.

    For additional information, visit CardiumTHX.com

    Please see disclaimer on the MissionIR website www.missionir.com/disclaimer.html

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.